论文部分内容阅读
目的研究耐药基因CA916798在肺癌患者化疗前后肿瘤组织中的表达及意义。方法收集2016年3-12月在我院行纤支镜活检、病理确诊的肺癌患者17例,采用实时定量PCR(qRT-PCR)以及免疫组化的方法分析肺癌组织中CA916798基因mRNA及蛋白在化疗前后的表达。结果 17例肺癌患者经过2个周期规范的前期化疗后,10例患者临床有效(病灶完全缓解或部分缓解),总体有效率为58.82%。化疗无效组CA916798基因mRNA表达显著高于化疗有效组(P<0.05);前期化疗前,化疗无效组和化疗有效组CA916798蛋白表达阳性率差异无统计学意义;前期化疗后,化疗无效组CA916798蛋白表达阳性率显著高于化疗有效组(P<0.05)。前期化疗后病灶稳定的患者中,再次化疗无效者,其CA916798基因表达在前期化疗后显著上调(P<0.05)。结论肺癌患者肿瘤组织中CA916798基因的表达变化与化疗效果相关,可能成为预测肺癌化疗敏感性的新的参考指标。
Objective To study the expression and significance of drug resistance gene CA916798 in tumor tissues of patients with lung cancer before and after chemotherapy. Methods Seventeen patients with lung cancer diagnosed by fiberoptic biopsy and pathology in our hospital from March to December in 2016 were enrolled in this study. Real-time quantitative PCR (qRT-PCR) and immunohistochemistry were used to analyze the expression of CA916798 mRNA and protein in lung cancer Chemotherapy before and after the expression. Results Seventeen patients with lung cancer underwent 2 cycles of pre-chemotherapy, and 10 patients were clinically effective (complete remission or partial remission) with an overall effective rate of 58.82%. The mRNA expression of CA916798 in chemotherapy-ineffective group was significantly higher than that in chemotherapy-effective group (P <0.05). There was no significant difference in the positive rate of CA916798 protein expression between chemotherapy-ineffective group and chemotherapy-effective group before chemotherapy, The positive expression rate was significantly higher than that of chemotherapy group (P <0.05). Among the patients with stable lesion before chemotherapy, the expression of CA916798 gene was significantly up-regulated after chemotherapy (P <0.05). Conclusion The expression of CA916798 gene in lung cancer patients is related to the effect of chemotherapy, which may be a new reference index for predicting chemosensitivity of lung cancer.